Related Experiment Video
Updated: Jul 20, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma
Xiu Feng Hu1, Eunice Yang, Jie Li
1Cancer Immunotherapy Laboratory, Burnet Institute Incorporating Austin Research Institute, Studley Road, Heidelberg, Victoria 3084, Australia. xf.hu@burnet.edu.au
Abstract:
Ovarian cancer is often a lethal disease, since the occult progression of the tumor within the peritoneal cavity results in late diagnosis and treatment failure. The identification of molecular events specific to metastasis is critical for the development of effective therapies. MUC1 is aberrantly overexpressed by most ovarian cancer and regarded as a molecular target for ovarian cancer. This review focuses on the latest advances regarding a signaling region in the MUC1 C-terminal subunit-mediated c-Src signaling pathways in malignant transformation, invasion and metastasis. Disruption of MUC1-C-terminal subunit-associated c-Src signaling by targeting the specific sites might represent a novel immunotherapeutic approach for the treatment of ovarian cancer.
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
